Patents Assigned to FORMYCON AG
-
Publication number: 20250229010Abstract: The present invention relates to a pre-filled syringe containing a VEGF antagonist and comprising a plastic barrel which is silicone-free, kits comprising this syringe and the use of the syringe for the administration of a VEGF antagonist in the treatment of ocular diseases.Type: ApplicationFiled: April 3, 2025Publication date: July 17, 2025Applicant: FORMYCON AGInventor: Bernd FIEDLER
-
Publication number: 20250082737Abstract: The present invention relates to fusion proteins of ACE2 with IgM or IgG2 Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.Type: ApplicationFiled: July 29, 2022Publication date: March 13, 2025Applicant: Formycon AGInventors: Johann Sebastian BUCHNER, Hristo Lyubomirov SVILENOV
-
Publication number: 20250027067Abstract: The present invention relates to fusion proteins of ACE2 with IgG Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2, as well as methods of producing them.Type: ApplicationFiled: November 24, 2022Publication date: January 23, 2025Applicant: Formycon AGInventors: Alwin REITER, Carsten BROCKMEYER, Florian WOLSCHIN
-
Publication number: 20240287185Abstract: The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising acitrate buffer, one or more amino acids other than histidine and a surfactant.Type: ApplicationFiled: June 22, 2022Publication date: August 29, 2024Applicant: Formycon AGInventors: Rainer Sigl, Katharina Maria Schott
-
Publication number: 20240139296Abstract: The present invention relates to pharmaceutical compositions of ACE2 Fc fusion proteins and therapeutic uses thereof, in particular in the treatment of infections with SARS-CoV-2.Type: ApplicationFiled: March 3, 2022Publication date: May 2, 2024Applicant: Formycon AGInventors: Alwin REITER, Rainer SIGL
-
Patent number: 11666632Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.Type: GrantFiled: February 26, 2022Date of Patent: June 6, 2023Assignees: FORMYCON AG, SIO2 MEDICAL PRODUCTS, INC., KLINGE BIOPHARMA GMBHInventors: Carsten Brockmeyer, Christopher Weikart, Murray Stephen Bennett, Jean-Pierre Giraud, Thomas Strungmann
-
Publication number: 20220362441Abstract: The present invention relates to a pre-filled syringe containing a VEGF antagonist and comprising a plastic barrel which is silicone-free, kits comprising this syringe and the use of the syringe for the administration of a VEGF antagonist in the treatment of ocular diseases.Type: ApplicationFiled: July 18, 2022Publication date: November 17, 2022Applicant: FORMYCON AGInventor: Bernd FIEDLER
-
Patent number: 11298405Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.Type: GrantFiled: January 21, 2021Date of Patent: April 12, 2022Assignees: FORMYCON AG, SIO2 MEDICAL PRODUCTS, INC., KLINGE BIOPHARMA GMBHInventors: Carsten Brockmeyer, Christopher Weikart, Murray Stephen Bennett, Jean-Pierre Giraud, Thomas Strungmann
-
Patent number: 10576128Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.Type: GrantFiled: January 26, 2017Date of Patent: March 3, 2020Assignee: FORMYCON AGInventor: Rainer Sigl
-
Patent number: 10568951Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.Type: GrantFiled: November 13, 2014Date of Patent: February 25, 2020Assignee: FORMYCON AGInventor: Rainer Sigl
-
Publication number: 20190030123Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.Type: ApplicationFiled: January 26, 2017Publication date: January 31, 2019Applicant: FORMYCON AGInventor: Rainer SIGL
-
Publication number: 20180326126Abstract: The present invention relates to a pre-filled syringe containing a VEGF antagonist and comprising a plastic barrel which is silicone-free, kits comprising this syringe and the use of the syringe for the administration of a VEGF antagonist in the treatment of ocular diseases.Type: ApplicationFiled: November 18, 2016Publication date: November 15, 2018Applicant: FORMYCON AGInventor: Bernd FIEDLER
